TY - JOUR T1 - IL-13 is a driver of COVID-19 severity JF - medRxiv DO - 10.1101/2020.06.18.20134353 SP - 2020.06.18.20134353 AU - Alexandra N. Donlan AU - Tara E. Sutherland AU - Chelsea Marie AU - Saskia Preissner AU - Ben T. Bradley AU - Rebecca M. Carpenter AU - Jeffrey M. Sturek AU - Jennie Z. Ma AU - G. Brett Moreau AU - Jeffrey R. Donowitz AU - Gregory A. Buck AU - Myrna G. Serrano AU - Stacey L. Burgess AU - Mayuresh M. Abhyankar AU - Cameron Mura AU - Philip E. Bourne AU - Robert Preissner AU - Mary K. Young AU - Genevieve R. Lyons AU - Johanna J. Loomba AU - Sarah J Ratcliffe AU - Melinda D. Poulter AU - Amy J. Mathers AU - Anthony Day AU - Barbara J. Mann AU - Judith E. Allen AU - William A. Petri, Jr. Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/01/2020.06.18.20134353.abstract N2 - Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here we report that elevated interleukin-13 (IL-13) was associated with the need for mechanical ventilation in two independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab had less severe disease. In SARS-CoV-2 infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti-IL-13 treatment in infected mice, in the lung, hyaluronan synthase 1 (Has1) was the most downregulated gene and hyaluronan accumulation was decreased. Blockade of the hyaluronan receptor, CD44, reduced mortality in infected mice, supporting the importance of hyaluronan as a pathogenic mediator, and indicating a new role for IL-13 in lung disease. Understanding the role of IL-13 and hyaluronan has important implications for therapy of COVID-19 and potentially other pulmonary diseases.Summary L-13 levels are elevated in patients with severe COVID-19. In a mouse model of disease, IL-13 neutralization results in reduced disease and lung hyaluronan deposition. Similarly, blockade of hyaluronan’s receptor, CD44, reduces disease, highlighting a novel mechanism for IL-13-mediated pathology.Competing Interest StatementWilliam A. Petri, Jr. receives research funding from Regeneron, Inc. which is the maker of Dupilumab.Funding StatementThis work was supported by grants to WP from the Manning Family Foundation, Ivy Foundation, Henske Family and NIH R01 AI124214. CM was supported by R01 AI148518, SB by NIH R01 AI146257, JS by NIH UL1TR003015/ KL2TR003016, BB by the Department of Laboratory Medicine and Pathology, University of Washington, JA by the Wellcome Trust 106898/A/15/Z, Wellcome Trust 203128/Z/16/Z and MRC- UK MR/K01207X/2, TES by the Asthma UK & Medical Research Foundation MRFAUK-2015-302, SP, RP by German Research Foundation (DFG): PR1562/1-1, TRR295, KFO339, and JL and SR by NCATS U24 TR002306 and UVA UL1 TR003015. Portions of this work were also supported by the UVA School of Data Science and by NSF CAREER award MCB-1350957 (C. Mura).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of biological specimens and de-identified patient information was approved by the University of Virginia Institutional Review Board (IRB-HSR #22231 and 200110). All procedures performed in this study were approved by the Virginia Commonwealth University Institutional Review Board and in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants or by their legally authorized representatives if they were unable to give consent. IRB Protocol #HM20019182All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available online when the peer-reviewed manuscript is published. ER -